# Nuvectis Pharma, Inc. (NVCT)

> Source: Nexqual · https://nexqual.com/NVCT · data as of 2026-10-28 20:00 UTC · cite as "Nexqual, Nuvectis Pharma, Inc. (NVCT), nexqual.com/NVCT" · informational, not investment advice.

**Price:** USD 18.36 (-0.43% on the day) · last close of Oct 28, 2026; US market pre market, not a live price. Prev close 18.44 · day 17.91–18.83 · 52w 5.55–29.28 · market cap $599M · NCM

## Key facts
- Insider open-market purchases, last ~7 months: 1 Form 4 filing, $916K; 1 by opportunistic insiders, 0 by routine insiders.
- Analysts: Buy (mean 1.67 on a 1–5 scale) (6 analysts), mean target USD 35.4 (range 30–40).
- Total return with dividends: 1Y +171.2% vs S&P 500 +13.6%; 5Y +464.9% vs S&P 500 +79.8%.
- Next earnings: 2026-11-03, EPS estimate USD -0.24, revenue estimate $0K.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Operating income | -$12.9M | -$19.2M | -$22.9M | -$19.8M | -$27.6M | -$28.9M |
| Net income | -$12.9M | -$19.1M | -$22.3M | -$19.0M | -$26.4M | -$27.8M |
| EPS (diluted) | -$3.02 | -$1.51 | -$1.43 | -$1.11 | -$1.32 | — |
| Cash + short-term investments | $5.7M | $20.0M | $19.1M | $18.5M | $31.6M | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/B 66.0x · Earnings yield -4.65%

## Insider purchases (SEC Form 4, open-market, last ~7 months)
1 purchase, $916K. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-06-30 | Mosseri Marlio Charles |  | 50,000 | $916K | 18.32 | Opportunistic (traded every year 2023–2025, no repeating month) |
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Analysts
Consensus Buy (mean 1.67 on a 1–5 scale), 6 analysts; mean target USD 35.4 (low 30, high 40).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-24 | HC Wainwright & Co. | Reiterated | Buy | $39 |
| 2026-08-24 | Cantor Fitzgerald | Initiated | Overweight |  |
| 2026-07-06 | Roth Capital | Target raised | Buy | $20 → $33 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-29) | 5Y (from 2022-01-31) |
|---|---|---|
| Total return | +171.2% | +464.9% |
| S&P 500 (SPY) | +13.6% | +79.8% |
| Per year | +172.1% | +44.1% |
| Volatility (annualized) | 86.5% | 100.8% |
| Max drawdown | -36.9% (Jun 2026→Oct 2026) | -76.0% (May 2022→Dec 2024) |

## Peers (Biotechnology)
LGND (Ligand Pharmaceuticals Incorpor) USD 318.78 +2.26% · RYTM (Rhythm Pharmaceuticals, Inc.) USD 91.97 -0.23% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.81 +1.58% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.9 +2.14% · AXSM (Axsome Therapeutics, Inc.) USD 143.51 +0.92% · PRAX (Praxis Precision Medicines, Inc) USD 285.48 +6.69%

## More
Full page: https://nexqual.com/NVCT · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Company outlook (8-K filed 2026-08-04)

- "Bentsur concluded, “As expected following an in-licensing transaction that involves a late-stage asset with a multi-billion-dollar market potential, our main focus now is to advance ciprocopan toward a marketing application in the United States and other key territories, with NXP200 and NXP900 driving potential longer-term upside in the oncology segment."
- "The marketing application in China for the treatment of PNH patients previously treated with anti C5 therapy is under review. o U.S. regulatory efforts underway; a pre-investigation new drug (“IND”) meeting with the Food and Drug Administration (“FDA”) followed by IND submission expected in 4Q2026. ·"
- "IND submission expected in 4Q2026. ·"
- "Non-small cell lung cancer (NSCLC): the clinical trial evaluating the combination of NXP900 plus osimertinib (Tagrisso™) in patients with NSCLC EGFR+ who initially responded to, and later progressed on, osimertinib, is ongoing, and we expect to provide an update by the end of this year."

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $-0.24 | $-0.25 | $0.00 | $0 | 6 |
| Next quarter (ends 2026-12-31) | $-0.25 | $-0.25 | $0.00 | $0 | 6 |
| Current fiscal year (ends 2026-12-31) | $-1.04 | $-1.01 | −$0.04 | $0 | 6 |
| Next fiscal year (ends 2027-12-31) | $-1.15 | $-1.01 | −$0.14 | $0 | 6 |

## Options: expected move (Cboe, 15-min delayed)

Expected move by 2026-11-20 (includes earnings 2026-11-03): ±17.8%; last 8 reports averaged ±11.1%.

| Expiration | Days | ATM IV | Expected move |
|---|---|---|---|
| 2026-11-20 | 22 | 88.8% | ±17.8% |
| 2026-12-18 | 50 | 87.2% | ±25.7% |
| 2027-01-15 | 78 | 87.8% | ±31.9% |
| 2027-04-16 | 169 | 85.9% | ±44.8% |

## Earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| Aug 4, 2026 | Quarter ended Jun 30, 2026 | −$0.30 | −$0.26 | Miss −15.4% | -10.8% |
| May 5, 2026 | Quarter ended Mar 31, 2026 | −$0.26 | −$0.31 | Beat +16.1% | +12.5% |
| Feb 11, 2026 | Quarter ended Dec 31, 2025 | −$0.31 | −$0.31 | In line | +0.7% |
| Nov 4, 2025 | Quarter ended Sep 30, 2025 | −$0.44 | −$0.25 | Miss −76.0% | -11.2% |
| Aug 5, 2025 | — | — | — | — | -11.4% |
| May 6, 2025 | — | — | — | — | -6.5% |
| Feb 25, 2025 | — | — | — | — | -6.8% |
| Nov 5, 2024 | — | — | — | — | +29.2% |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

## Recent SEC filings (last 120 days)
| Filed | Form | What it says | Filing |
|---|---|---|---|
| 2026-08-21 | 8-K | Other material event — “Establishment of "At the Market" Offering Program On August 21, 2026, Nuvectis Pharma, Inc., a Delaware corporation (the "Company"), entered into an Open Market Sale Agreement SM (the "Sale Agreement") with Jefferies LLC ("Jefferies") as sales agent, pursuant to which the Company may offer and sell shares (the "ATM Shares") of its common stock, $0.00001 par value per share (the "Common Stock"), from time to time through Jefferies. On August 21, 2026, the Company expects to file a prospectus supplement (the…” | https://www.sec.gov/Archives/edgar/data/1875558/000110465926099712/0001104659-26-099712-index.htm |
| 2026-08-06 | Schedule 13G | Soleus Private Equity Fund III, L.P., Soleus Private Equity GP III, LLC: 5.1% of shares, passive 5%+ holder | https://www.sec.gov/Archives/edgar/data/1875558/000121390026085988/0001213900-26-085988-index.htm |
| 2026-08-04 | 10-Q | Quarterly report · period ended Jun 30, 2026 | https://www.sec.gov/Archives/edgar/data/1875558/000110465926090109/0001104659-26-090109-index.htm |
| 2026-08-04 | 8-K | Quarterly results | https://www.sec.gov/Archives/edgar/data/1875558/000110465926090094/0001104659-26-090094-index.htm |
Source: SEC EDGAR. Quotes are the opening words of each item as filed.